Pharmacogenomics
Mostrando 1-12 de 18 artigos, teses e dissertações.
-
1. Pharmacogenomics of sevoflurane: role in emergence delirium
Rev. Bras. Anestesiol.. Publicado em: 10/10/2019
-
2. Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo / Hypolipemiant effects on CYP3A4 and CYP3A5 mRNA expression in vitro and in vivo
Introdução: As CYP3A4 e CYP3A5 são enzimas do citocromo P450 responsáveis pela biotransformação de esteróides endógenos e vários fármacos, entre eles as estatinas. Polimorfismos nos genes CYP3A4 e CYP3A5 (CYP3A4*1B, CYP3A5*3C e CYP3A5*1D) foram associados com diferenças na resposta hipolipemiante de indivíduos tratados com atorvastatina e sinvast
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 07/10/2011
-
3. Análise farmacogenômica de pacientes submetidos à dupla antiagregação plaquetária / Pharmacogenomics analysis of patients undergoing double platelet antiagregation
O presente estudo avaliou o perfil farmacogenômico de 338 pacientes, sob terapia antiagregante. Os pacientes foram submetidos a tratamento prévio com AAS (100mg/dia) e clopidogrel (75mg/dia) por no mínimo cinco dias antes da angioplastia coronária. Os indivíduos com resposta considerada indesejada <30% de inibição de PRU (do inglês, P2RY12 Reaction U
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 11/08/2011
-
4. The fallacy of racial pharmacogenomics
Personalized pharmacogenomics aims to use individual genotypes to direct medical treatment. Unfortunately, the loci relevant for the pharmacokinetics and especially the pharmacodynamics of most drugs are still unknown. Moreover, we still do not understand the role that individual genotypes play in modulating the pathogenesis, the clinical course and the susc
Brazilian Journal of Medical and Biological Research. Publicado em: 2011-04
-
5. Proteção do genoma humano e socioambientalismo : aspectos bioéticos e jurídicos
The build of the socio-environment paradigm is resultant from the comprehension that isolated protection is not possible, implying collective care. The human being, as a biodiversity integrant, is supported by his laws, but also by environment laws. The human genome is unique for each individual and distinguishes itself from the others beings of the same spe
Publicado em: 2009
-
6. Pharmacogenetics, pharmacogenomics and airway disease
The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients: pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA level in targets for medication, and variability in response
BioMed Central.
-
7. Pharmacogenomics.
The American Society of Human Genetics.
-
8. Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
American Society of Clinical Oncology.
-
9. Criteria influencing the clinical uptake of pharmacogenomic strategies
Pharmacogenomics and related genomic technologies may hold the potential to improve efficacy and safety in prescription, but complex factors affect their clinical success
BMJ Publishing Group Ltd..
-
10. Pharmacogenomics arrives
We've had the human genome sequence for a little while now, and it looks as though we're still some way off being able to exclude from most clinical trials those people who will probably suffer side effects.
BioMed Central.
-
11. Human Glucocorticoid Receptor α Gene (NR3C1) Pharmacogenomics: Gene Resequencing and Functional Genomics
Context: The human glucocorticoid receptor α (GRα) is a nuclear hormone receptor that regulates multiple physiological and pathophysiological processes. There are large variations in both physiological and therapeutic response to glucocorticoids. Multiple previous studies suggested that genetic polymorphisms in GRα (NR3C1) might play an important role.
The Endocrine Society.
-
12. 22nd European Workshop for Rheumatology Research, Leiden, The Netherlands, 28 February–3 March 2002
The European Workshop for Rheumatology Research met this year in Leiden, The Netherlands. The Workshop provided a platform to feast on new technologies and how they have taken research programmes forward. While there will be the inevitable delay during which mechanisms are devised for analysing the huge amount of information generated by these technologies,
BioMed Central.